Squarepoint
RNA

Squarepoint’s Atrium Therapeutics RNA Stock Holding History

Squarepoint’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.97M Sell
146,743
-84,723
-37% -$1.11M ﹤0.01% 2352
2026
Q1 		$3.09M Buy
+231,466
New +$3.25M ﹤0.01% 1868

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Squarepoint's RNA Position: Q2 2026 in Review

Squarepoint reduced its Atrium Therapeutics (RNA) stake by 37% in Q2 2026, selling an estimated $1.11M and leaving 146,743 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2352.

Squarepoint first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.09M in Q1 2026. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • Squarepoint held 146,743 shares of Atrium Therapeutics worth $1.97M as of Q2 2026.
  • Squarepoint sold 84,723 Atrium Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Atrium Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2352 holding.
  • Squarepoint first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Squarepoint's Atrium Therapeutics position peaked at $3.09M in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.